All fields are required.

Close Appointment form

Board of Directors

Improving patient outcomes with innovative drug therapies.

Lisa Colleran


Lisa Colleran has served as a Director on our Board since March 2018.

Ms. Colleran is the Principal of LNC Advisors, a strategic consulting firm that specializes in assisting biotech, pharmaceutical and medical device companies. She also currently serves on the Board of Directors for Establishment Labs and Ariste Medical.

Prior to founding LNC Advisors, Ms. Colleran served as Chief Executive Officer of LifeCell Corporation and a Board Member for Centaur Guerney, the holding company for LifeCell Corporation. From 2013 to 2018, Ms. Colleran also served as the Global President of LifeCell Corporation. Prior to assuming the role of Global President, Ms. Colleran served in numerous other roles at LifeCell, enhancing her expertise in marketing, business development and commercial operations. Before joining LifeCell, Ms. Colleran spent 20 years at Baxter Healthcare in the Renal Division and her last position there was Vice President and General Manager of Renal Pharmaceuticals.

Ms. Colleran received her BSN from Molloy College and her MBA from Loyola University of Chicago.

John Cooper


John Cooper has served as a Director on our Board and Chair of the Audit Committee since September 2017.

Mr. Cooper’s career spans over 30 years of senior executive experience managing publicly-traded companies in the life sciences industry. He has played key leadership roles building companies with transformational medical technologies, including the first FDA approved synthetic peptide-containing pulmonary surfactant for premature infants with severe respiratory disease and the second FDA approved blood diagnostic test for HIV. Mr. Cooper has significant experience in corporate and organization development, raising capital, mergers and acquisitions, strategic alliances, investor relations, and corporate governance. Over his career, Mr. Cooper has raised approximately $1 billion in capital through various financing and strategic transactions. Currently, Mr. Cooper provides corporate development and financial advisory services to emerging public and private companies in the life sciences industry.

Mr. Cooper held executive leadership positions for Windtree Therapeutics (formerly Discovery Laboratories), a specialty biopharmaceutical company focused on respiratory therapeutics, from 2001 to 2016. His roles included President, Chief Executive Officer and Member of the Board of Directors, President and Chief Financial Officer, Executive Vice President and Chief Financial Officer. Prior to Discovery Labs, Mr. Cooper served as Senior Vice President and Chief Financial Officer at Chrysalis International Corporation (acquired by Phoenix Life Sciences) and its predecessor DNX Corporation, where he managed its initial public offering and negotiated and integrated several strategic acquisitions. Previously, Mr. Cooper served in senior financial management and executive committee roles at ENI Diagnostics (acquired by Pharmacia AB).

Mr. Cooper received his B.S. in Commerce from Rider University and holds a CPA designation.

Mark Ravich


Mark Ravich has served as a Director on our Board since June 2017.

Mr. Ravich is the President of Tri-Star Management, which he co-founded in 1998. Additionally, he serves as the chief manager of various real estate entities. He is also a Director of Dilion Technologies and Orchids Paper Products Company, where he serves as Chairman of its Governance Committee and a Member of its Audit Committee. Previously, from 1990 until its sale in 1998, Mr. Ravich served as the Chief Executive Officer and a Director of Universal International.

Mr. Ravich received his BSE and MBA, Magna Cum Laude, from the Wharton School of the University of Pennsylvania.

Robin Smith, M.D.


Robin Smith, M.D., has served as an Independent Director on our Board since June 2016.

Dr. Robin L. Smith, age 54, is a business leader, entrepreneur, doctor and philanthropist and uniquely positioned assist public companies and health care systems advance and be successful in rapidly evolving health care industry. She received her BA from Yale, MD from the Yale School of Medicine and an MBA from the Wharton School of Business and completed the Stanford University Directors Program. Dr Smith is a building and trailblazer in the field of regenerative medicine and predictive analytics and has focused on turn-arounds, M & A and disruptive innovations driving interest and growth.

Dr Smith has served as an independent director on multiple public company boards and has served or chaired multiple committees including audit, nominating and governance, compensation and science and technology. Dr Smith served as Chairman and CEO NASDAQ:NBS where she pioneered the company’s innovative business model, combining proprietary cell therapy development with a successful contract development and manufacturing organization which was sold to Hitachi for $100m dollars. Dr. Smith raised over $200 million, completing six acquisitions and one divestiture while during her 9 year tenure, the company won an array of industry awards and business recognition including a first-place ranking in the tri-state area (two years in a row), and eleventh place nationally, on Deloitte’s Technology Fast 500, and Frost & Sullivan’s North American Cell Therapeutics Technology Innovation Leadership Award.

Dr Smith joined the board of CNS Response in 2015, a bulletin board debt ridden company developing a clinical decision support tool for the treatment of non-psychotic mental health diagnosis. Through her leadership as Chairman, she raised capital, restructuring the company and up listed it to NASDAQ (MYND). Through M&A and recruiting new leadership, she has put the company in a position to be a leading behavioral organization with tools and technologies to address an unmet medical improving access to care and lowering cost. Dr Smith also joined the Seelos Therapeutics (NASDAQ: SEEL). She additionally is co-chairs the Life Sci advisory board on gender diversity, serves on Sanford Health’s International Board, Alliance for Regenerative Medicine (ARM) Foundation board and the board of overseers at the NYU Langone Medical Center in New York. She previously served on the board of trustees of the NYU Langone Medical Center and is the past chairman of the board of directors for the New York University Hospital for Joint Diseases. She was also appointed as clinical associate professor, Department of Medicine at the Rutgers, New Jersey Medical School in 2017.

Dr. Smith coauthored two books: Cells Are the New Cure (2017) and The Healing Cell: How the Greatest Revolution in Medical History Is Changing Your Life (2013). Dr. Smith has been widely recognized for her leadership in health care and has received the Regenerative Medicine Foundation (RMF) 2019 Stem Cell and Regenerative Medicine Action Award for International Diplomacy in 2019 and the 2018 HEALinc Future Health Humanitarian Award. She has been widely recognized for her work as a female entrepreneur and received the Business Intelligence Group’s Woman of the Year Award in 2018 and the 2018 Gold Stevie® Award for Woman of the Year – Government of Non-Profit. She is also a winner of the 2014 Brava! Award, which recognizes top women business leaders in the Greater New York area. Dr. Smith was elected to the 2018 NACD Directorship 100: Directors list by the NACD Directorship magazine for her work and expertise in corporate governance. She was also a finalist for the 2014 EY Entrepreneur of the Year Award for the New York area, recognizing entrepreneurs who demonstrate excellence and success in the areas of innovation, financial performance, and personal commitment to their businesses and communities. In April 2016, Pope Francis awarded Dr. Smith Dame Commander with Star Pontifical Equestrian Order of Saint Sylvester Pope and Martyr. Dr. Smith was awarded the Lifetime Achievement in Healthcare and Science Award by The National Museum of Catholic Art and Library in May 2017.

Benjamin Wolin

Board Chairman

Benjamin Wolin has served as a Director and Chairman of our Board since March 2018.

Mr. Wolin is also the Lead Independent Director of Diplomat Pharmacy (DPLO), Director of Covetrus (CVET) and serves as an advisor to 3L Capital.

From 2002 to 2016, Mr. Wolin was the Co-founder, Chief Executive Officer and a Member of the Board of Directors of Everyday Health (EVDY), a leading provider of digital health and wellness solutions, until its sale to a subsidiary of j2 Global (JCOM).

Mr. Wolin received his B.A. from Bowdoin College.